In addition to this preliminary but encouraging result, we also reported our subsequent results. 3 Sixty patients with AML were treated with the G-CSF-combined BEA regimen followed by auto-PBSCT. The 5-year probability of disease-free survival and 3-year probability of relapse were 70.7% and 21.4% in 42 patients transplanted during CR1, respectively. Oral mucositis and gastrointestinal symptoms were common toxicities related to G-CSF-combined BEA. Oral toxicity greater than grade II was observed in 23% of the patients. There was no early transplant-related mortality (TRM) within 100 days in patients transplanted in CR1. The median day to recovery of granulocytes Ͼ500/l was 15 (range, 8-44), and the median time to the last platelet transfusion was 24 days (range 0-Ͼ180).
In order to assess these encouraging results, we conducted a multicenter early phase II study of auto-PBSCT for AML in CR1. 4 Fifty-six of 105 enrolled patients received auto-PBSCT; 50 patients were conditioned with G-CSFcombined BEA and six with BU/CY regimen. Engraftment and regimen-related toxicity were almost similar to our previous studies.
2,3 TRM at day 100 was observed in 4/50 (8%) receiving the G-CSF-combined BEA regimen. Disease-free survival is estimated to be 62.0% at a median follow-up time of 534 days.
In our studies, treatment-related toxicities such as mucositis and diarrhea were observed relatively frequently as Kim et al described, but most of them were tolerable and the incidence of TRM was low. [2] [3] [4] Similar to their data, we have also experienced delayed recovery of platelets in some patients. Our data clearly indicated that granulocyte and platelet recoveries inversely correlated with the number of CFU-GM infused. 3 In contrast, however, the relapse rate of leukemia after auto-PBSCT was not high compared with that reported by Kim et al. 1 This might be partly because of a selection bias that 22 out of 42 (52%) patients transplanted in CR1 were M2 and M3 types according to the FAB classification. 3 Another possible explanation for this relatively low relapse rate of leukemia is the degree of leukemic cell contamination in PBSC harvest products. We have previously reported that the degree of leukemic contamination may decrease as chemotherapy is repeated. 5 Therefore, the second PBSC harvest, which was collected during hematologic recovery after the second consolidation chemotherapy, was preferentially used instead of the first PBSC harvest for transplantation, if a sufficient number of CFU-GM had been obtained (CFU-GM Ͼ1 × 10
